Advertisement

OB/GYN General

EC Retroperitoneal Staging: Long-term Outcomes of Approaches

Oct 04, 2022

For the treatment of obvious early-stage endometrial cancer (EC), sentinel lymph node mapping (SNM) has become increasingly popular. Here, researchers examined how well 3 distinct methods of nodal ass...

Adjuvant Chemotherapy Delay for FIGO stage I EOC Patients

Oct 04, 2022

Patients with epithelial ovarian cancer (EOC) are encouraged to have adjuvant chemotherapy administered no later than 42 days after surgery. This research aimed to determine whether or not postponing ...

MOST Indexes and HRQL in Recurrent Ovarian Cancer

Oct 04, 2022

Patients with recurrent ovarian cancer can evaluate the efficacy and safety of palliative chemotherapy by using the Measure of Ovarian Symptoms and Treatment (MOST) concerns; a validated patient-repor...

Pembrolizumab Monotherapy HRQoL: MSI-H/dMMR Deficient EC Patients'

Oct 04, 2022

In the phase 2 multi-cohort KEYNOTE-158 study, pembrolizumab showed an objective response rate that was clinically significant in patients with advanced MSI-H/dMMR endometrial cancer who had had prior...

MIS Vs. OPS in High-risk Histologic EC Patients

Oct 04, 2022

Patients with high-risk histology endometrial cancer (EC; grade 3 endometrioid adenocarcinoma, papillary serous carcinoma [PS], clear cell carcinoma [CC], and carcinosarcoma) were compared between min...

Niraparib Plus Bevacizumab Maintenance Therapy in Advanced Ovarian Cancer

Oct 04, 2022

To examine the safety and efficacy of niraparib+bevacizumab as first-line maintenance therapy for patients with newly diagnosed advanced ovarian cancer. This multicenter, phase II, single-arm, open-la...

Pembrolizumab Patients Treated with Advanced Vulvar SCC

Oct 04, 2022

Treatment options for advanced vulvar cancer are limited. Researchers evaluated pembrolizumab monotherapy in patients with advanced vulvar squamous cell carcinoma (SCC) enrolled in phase 2 multicohort...

In Advanced Epithelial Ovarian Cancer Patients (AEOC), PCS Outcome and Treatment Plan Are Described

Oct 03, 2022

A multidisciplinary agreement was used to determine whether or not patients diagnosed with advanced epithelial ovarian cancer (AEOC) between October 2018 and October 2020 should receive primary chemot...

The Laparoscopic Approach to TAP Blocks Is a Useful and Effective Alternative to US Guided TAP Blocks

Oct 03, 2022

The goal of this study was to compare the efficacy of an ultrasound-guided block (US-Tap) and laparoscopically-guided transversus abdominis plane block (Lap-Tap) with liposomal bupivacaine in the trea...

BRCA-Mutated and Homologous Recombination Deficient Ovarian Cancer Treated with Olaparib

Oct 03, 2022

For patients with BRCA1/BRCA2-mutated (BRCAm), platinum-sensitive relapsed ovarian cancer (PSROC), and 2 prior lines of platinum-based chemotherapy, the SOLO3 phase III trial found that treatment with...

Laparoscopic Approach to Cervical Cancer (LACC) trial findings oppose ours

Oct 03, 2022

As shown by the Laparoscopic Approach to Cervical Cancer (LACC) trial, early-stage cervical carcinoma patients who undergo a minimally invasive (MIS) radical hysterectomy have poorer oncologic outcome...

Can Intraperitoneal Chemotherapy Cure Patients with Stage 3 Ovarian Cancer?

Oct 03, 2022

If a patient with advanced epithelial ovarian cancer (EOC) lives without disease progression for 10 years after diagnosis, they are considered to be cured. Researchers describe the percentage of patie...

Combining Pannisertib and Serabelisib with Paclitaxel for Advanced Solid Tumors

Oct 03, 2022

Researchers claim that they conducted a Phase I trial to assess the efficacy and safety of paclitaxel, sapanisertib, and serabelisib. This was an open-label cohort trial comparing sapanisertib (TAK-22...

Endometrial Cancer Staging Surgery: A Randomized Study Comparing Standard Counseling with Multimedia-Enhanced Counseling

Oct 03, 2022

According to researchers, a patient's understanding of surgery is often limited in the context of sophisticated oncologic operations. Supplemental materials can help patients learn more about their su...

Paclitaxel and Pazopanib for Ovarian Cancer Relapsing During Bevacizumab Maintenance

Oct 03, 2022

Recurrent ovarian cancer (rOC) responds well to anti-angiogenic therapy with bevacizumab in combination with chemotherapy; however, information on tyrosine kinase inhibitors following progression on m...

Gynecologic Oncology Preoperative Assessment and Prehabilitation Services Need to Be Standardized

Oct 03, 2022

The purpose of researchers was to determine if gynecologic cancer patients who undergo surgery have a higher risk of postoperative problems, readmissions, or discharge locations other than a home usin...

Impact of Individual Insurance Status On Survival of Cervical Cancer Patients

Oct 03, 2022

To investigate the relative contributions of individual insurance status and hospital payer mix (safety net status) to quality of care and survival for patients with cervical cancer. Researchers used ...

Bevacizumab & Rucaparib in Recurrent Carcinoma

Sep 15, 2022

Patients with recurrent cervical or endometrial cancer were included in this study to evaluate the safety and efficacy of combination bevacizumab rucaparib treatment. About 33 individuals were enrolle...

Niraparib Efficacy & Postoperative Residual Disease Status

Sep 15, 2022

The goal of this study was to determine if the effectiveness of first-line maintenance therapy with niraparib differs among patients with newly diagnosed advanced ovarian cancer based on the timing of...

Ovarian Cancer Cytoreductive Surgery: Major Postoperative Complications Impact

Sep 15, 2022

The purpose of this study is to determine whether or not substantial postoperative problems have a negative effect on survival for patients with advanced ovarian cancer who have undergone cytoreductiv...

SUBSPECIALTIES

Advertisement